Omega-3-acid ethyl esters

What it is

This is the prescription-strength form of marine omega-3 fatty acids, in which EPA and DHA are supplied as ethyl esters in a liquid-filled gel capsule. Each 1-gram capsule contains at least 900 mg of those ethyl esters, predominantly EPA at about 465 mg and DHA at about 375 mg, with alpha-tocopherol in soybean oil as an inactive ingredient. It differs from over-the-counter fish oil in strength, in being an ethyl ester rather than a triglyceride, and in being a regulated drug with one approved indication. It also differs from icosapent ethyl, which is a purified EPA-only ethyl ester with no DHA.

What the research says

The approved use is narrow and the evidence for it is clean: in two small randomised trials, 4 grams a day cut median triglycerides by about 45% against a 7% rise on placebo in adults whose triglycerides were at least 500 mg/dL, while median LDL cholesterol rose 44.5%. Everything beyond that is disputed. Large cardiovascular outcome trials of EPA plus DHA at 1 gram a day (VITAL, ASCEND) and at 4 grams a day (STRENGTH) found no reduction in major cardiovascular events, the 1999 GISSI-Prevenzione trial found a 10 to 15% relative risk reduction after myocardial infarction, and REDUCE-IT found a 25% relative reduction with EPA-only icosapent ethyl against a mineral oil comparator whose inertness is itself contested. A Cochrane review of 86 trials rated the evidence for no effect on all-cause mortality and cardiovascular events as high certainty, with a slight reduction in coronary heart disease events at low certainty. Meta-analysis of the outcome trials found an increased risk of atrial fibrillation, larger above 1 gram a day, and the Lovaza label itself carries a warning about recurrent atrial fibrillation.

Evidence grade: Disputed.

How it works

Drug class: Lipid-regulating agent; ethyl esters of the long-chain marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)

Each 1-gram capsule holds at least 900 mg of ethyl esters of omega-3 fatty acids from fish oil, mostly EPA (about 465 mg) and DHA (about 375 mg). How it lowers triglycerides is not fully settled; the label lists candidate mechanisms including inhibiting an enzyme that builds triglyceride, increasing fat burning in the liver, reducing fat synthesis there and raising lipoprotein lipase activity, and notes EPA and DHA are poor substrates for the enzymes that make triglyceride. (Source 1)

What it is used for

• The triglyceride-lowering effect is reproducible: about a 45% median fall against a 7% rise on placebo in the two approval trials, and a Cochrane review of 86 trials rated the roughly 15% dose-dependent triglyceride reduction as high-certainty evidence. What is not established is whether that translates into fewer events: the label states the effect on pancreatitis risk and on cardiovascular death and illness has not been determined, and LDL cholesterol rose 44.5% in the approval trials. Evidence: established. (Source 2)
• This is where the literature splits. GISSI-Prevenzione (1999, post-myocardial-infarction, 1 g/day) and REDUCE-IT (2019, EPA-only at 4 g/day against mineral oil) found benefit; VITAL and ASCEND at 1 g/day and STRENGTH at 4 g/day of EPA plus DHA found none, and STRENGTH was stopped early for futility. Cochrane rates the no-effect finding for all-cause mortality and cardiovascular events as high certainty, with a slight reduction in coronary heart disease events at low certainty. An independent analysis attributes part of the REDUCE-IT result to its mineral oil comparator; a manufacturer-aligned review disputes that. Evidence: disputed. (Source 3)
• The evidence points the other way. The label records a randomised trial in which more people on the drug had recurrent symptomatic atrial fibrillation or flutter than on placebo, and states it is not indicated for that condition. A meta-analysis of seven outcome trials found an increased risk of atrial fibrillation overall (HR 1.25) and more so above 1 gram a day (HR 1.49). Evidence: not-supported. (Source 4)

Interactions

• Warfarin, antiplatelet drugs and other agents affecting coagulation (label): Some omega-3 trials showed a longer bleeding time, though within normal limits and without clinically significant bleeding, and no trial has properly examined the combination. The label asks for periodic monitoring. Post-marketing reports include a bleeding tendency. (Source 5)
• Over-the-counter fish oil and other marine omega-3 supplements (clinical trial): Taking a fish oil supplement alongside the prescription product adds to the same EPA and DHA exposure. That matters because the atrial fibrillation signal in meta-analysis was dose-related, with a larger hazard ratio in the trials above 1 gram a day than at or below it. (Source 6)
• Fish and shellfish (in people with fish or shellfish allergy) (label): The ethyl esters are obtained from the oil of several fish sources. Whether people allergic to fish or shellfish are at higher risk of an allergic reaction to the drug is not known, and the label advises caution. Anaphylactic reaction appears in post-marketing reports. (Source 7)
• Meals and a lipid-lowering diet (label): The label states the drug was given with meals in the clinical studies, and that a lipid-lowering diet should be started before and continued during treatment. The approved indication is as an adjunct to diet, not instead of it. (Source 8)
• Beta blockers, thiazide diuretics and estrogens (label): These medicines can themselves push triglycerides up. The label asks that they be stopped or changed if possible before triglyceride-lowering drug treatment is considered, which makes them a reason a triglyceride level may be high in the first place. (Source 2)

Stopping it

• We found no withdrawal syndrome, rebound or deprescribing literature for omega-3-acid ethyl esters. What the literature does show is that the biochemical effect is the thing being maintained: Cochrane rated the roughly 15% dose-dependent triglyceride reduction as high certainty, so stopping removes that reduction, while the same review found little or no effect on mortality or cardiovascular events to lose. (Source 9)
• One trial recorded in the label bears on stopping in a specific group: in people with paroxysmal or persistent atrial fibrillation, the excess of recurrent symptomatic atrial fibrillation or flutter appeared particularly in the first two to three months of starting, and the label states the drug is not indicated for atrial fibrillation or flutter. (Source 4)

What goes wrong

A meta-analysis of seven cardiovascular outcome trials found marine omega-3 supplementation associated with a higher risk of atrial fibrillation, with a larger hazard ratio in the trials testing more than 1 gram a day. (Source 6)

• Meta-analysis, Moderate certainty.
• Size: 81,210 patients across 7 trials; 2905 atrial fibrillation events.
• Who: mean age 65, 39% female, enrolled in cardiovascular outcome trials.
• How long: weighted average follow-up 4.9 years.
• Result: overall HR 1.25 (95% CI 1.07-1.46, P=0.013); >1 g/d HR 1.49 (1.04-2.15, P=0.042); <=1 g/d HR 1.12 (1.03-1.22, P=0.024), P for interaction <0.001; per 1 g higher dose HR 1.11 (1.06-1.15, P=0.001)
• Funding: Research Support, N.I.H., Extramural per the PubMed record.

Limit of this finding: The source prints "per 1 g higher dosage of ɷ-3 fatty acids dosage", repeating the word dosage, and spells omega with a closed omega character rather than the usual Greek letter. Both are the journal's own characters and have been kept. Neither changes the figures.

In meta-analysis, the use of marine ɷ-3 fatty acid supplements was associated with an increased risk of AF (n=2905; HR, 1.25 [95% CI, 1.07-1.46]; P=0.013). In analyses stratified by dose, the HR was greater in the trials testing >1 g/d (HR, 1.49 [95% CI, 1.04-2.15]; P=0.042) compared with those testing ≤1 g/d (HR, 1.12 [95% CI, 1.03-1.22]; P=0.024; P for interaction <0.001). In meta-regression, the HR for AF increased per 1 g higher dosage of ɷ-3 fatty acids dosage (HR, 1.11 [95% CI, 1.06-1.15]; P=0.001). CONCLUSIONS: In RCTs examining cardiovascular outcomes, marine ɷ-3 supplementation was associated with an increased risk of AF. The risk appeared to be greater in trials testing >1 g/d.

The Lovaza label itself records a randomised trial in which the drug was followed by more recurrent atrial fibrillation or flutter than placebo in people who already had atrial fibrillation. (Source 4)

• Randomized trial, Low certainty.
• Size: 663 subjects (542 paroxysmal AF, 121 persistent AF)
• Who: people with symptomatic paroxysmal or persistent atrial fibrillation, median baseline TG 127 mg/dL, no substantial structural heart disease, in sinus rhythm at baseline.
• How long: 8 grams/day for 7 days then 4 grams/day for 23 weeks.
• Result: paroxysmal stratum 129 (47%) events on placebo versus 141 (53%) on drug, HR 1.19 (95% CI 0.93, 1.35); persistent stratum 19 (35%) versus 34 (52%), HR 1.63 (0.91, 2.18); both strata combined HR 1.25 (1.00, 1.40)
• Funding: trial recorded in the manufacturer's label.

Limit of this finding: Every one of the three hazard ratios in this trial either crosses 1.00 or touches it: 1.19 (0.93 to 1.35), 1.63 (0.91 to 2.18) and, for both strata combined, 1.25 (1.00 to 1.40). A confidence interval that includes or touches 1.00 means the result is compatible with no difference at all, which is why the label itself says the clinical significance is uncertain. Read this as a possible signal that the drug is not a treatment for atrial fibrillation, not as proof that it causes recurrences.

At 24 weeks, in the paroxysmal AF stratum, there were 129 (47%) first recurrent symptomatic AF or flutter events on placebo and 141 (53%) on LOVAZA (primary endpoint, HR: 1.19; 95% CI: 0.93, 1.35). In the persistent AF stratum, there were 19 (35%) events on placebo and 34 (52%) events on LOVAZA (HR: 1.63; 95% CI: 0.91, 2.18). For both strata combined, the HR was 1.25; 95% CI: 1.00, 1.40. Although the clinical significance of these results is uncertain, there is a possible association between LOVAZA and more frequent recurrences of symptomatic AF or flutter in patients with paroxysmal or persistent AF, particularly within the first 2 to 3 months of initiating therapy.

In pooled trial data the drug's own adverse reactions are mild and gastrointestinal, reported at low single-digit rates. (Source 10)

• Official position, Low certainty.
• Size: pooled data across 23 clinical trials; 655 on drug and 370 on placebo.
• Who: subjects with hypertriglyceridemia and severe hypertriglyceridemia.
• How long: not specified in the pooled summary.
• Result: reactions reported in at least 3% and more often than placebo: eructation 4% versus 1%, dyspepsia 3% versus 2%, taste perversion 4% versus under 1%.
• Funding: manufacturer-sponsored trials collated in the label.

Limit of this finding: These are counts and percentages out of 655 people on the drug and 370 on placebo, pooled across 23 trials, so 29 cases of eructation is 4% against 5 cases, or 1%, on placebo. The asterisk on the Adverse Reaction heading is the label's own footnote marker; its footnote, printed at the foot of the table, says the pooled trials included people with hypertriglyceridaemia and severe hypertriglyceridaemia, so these rates are not from people with ordinary triglyceride levels.

Adverse reactions reported in at least 3% of subjects treated with LOVAZA and at a greater rate than placebo based on pooled data across 23 clinical trials are listed in Table 1. Table 1. Adverse Reactions Occurring at Incidence ≥3% and Greater than Placebo in Clinical Trials of LOVAZA Adverse Reaction* LOVAZA (n = 655) Placebo (n = 370) n % n % Eructation 29 4 5 1 Dyspepsia 22 3 6 2 Taste perversion 27 4 1 <1 * Trials included subjects with hypertriglyceridemia and severe hypertriglyceridemia.

Post-approval reporting has added anaphylactic reaction, a bleeding tendency and urticaria, with no reliable frequency. (Source 11)

• Case series, Very low certainty.
• Size: spontaneous reports from a population of unknown size.
• Who: people taking the drug after approval.
• How long: post-approval.
• Result: no rates can be estimated; causality cannot always be established.
• Funding: regulatory pharmacovigilance.

Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure. The following events have been reported: anaphylactic reaction, hemorrhagic diathesis, urticaria.

Beyond the pooled table, the label lists further adverse reactions seen in the trials, including constipation and vomiting, raised liver enzymes, and itching and rash, with no rates attached. (Source 10)

• Official position, Low certainty.
• Size: not stated for these reactions; the pooled table covered 655 subjects on drug and 370 on placebo.
• Who: adults in the 23 pooled clinical trials of the drug.
• How long: trial durations not stated in this section.
• Result: no numbers are given for these reactions: the label lists them by body system only.
• Funding: manufacturer-sponsored trials collated in the label.

Limit of this finding: These are named without any frequency, so they cannot be compared with placebo. Two of them, increased ALT and increased AST, are blood tests of liver irritation rather than symptoms a person would notice.

Additional adverse reactions from clinical trials are listed below: Digestive System Constipation, gastrointestinal disorder, and vomiting. Metabolic and Nutritional Disorders Increased ALT and increased AST. Skin Pruritus and rash.

What the evidence supports

In the two trials the approval rests on, 4 grams a day lowered median triglycerides substantially against placebo, and raised median LDL cholesterol. (Source 12)

• Randomized trial, Moderate certainty.
• Size: 84 adults across 2 trials (42 on drug, 42 on placebo)
• Who: adults with baseline triglycerides between 500 and 2,000 mg/dL; median baseline TG 792 mg/dL.
• How long: 6 and 16 weeks.
• Result: median percent change TG -44.9% on drug versus +6.7% on placebo (difference -51.6); VLDL-C -41.7% versus -0.9%; non-HDL-C -13.8% versus -3.6%; HDL-C +9.1% versus 0.0%; LDL-C +44.5% versus -4.8% (difference +49.3)
• Funding: manufacturer trials submitted for approval.

Limit of this finding: Table 2 in the label prints its legend row ABOVE the data rows, so the line explaining that BL means baseline in mg/dL and that Difference is the LOVAZA median percent change minus the placebo median percent change sits between the column headings and the numbers. That is how the label is laid out; it is not a transcription error. Read these as median percent changes in 42 people per arm over 6 and 16 weeks, not as effects on any illness.

TG 816 -44.9 788 +6.7 -51.6 Non-HDL-C 271 -13.8 292 -3.6 -10.2 TC 296 -9.7 314 -1.7 -8.0 VLDL-C 175 -41.7 175 -0.9 -40.8 HDL-C 22 +9.1 24 0.0 +9.1 LDL-C 89 +44.5 108 -4.8 +49.3

The same Cochrane review found high-certainty evidence that long-chain omega-3 lowers triglycerides by about 15% in a dose-dependent way, with little or no effect on serious adverse events, body fat, other lipids or blood pressure. (Source 13)

• Systematic review, High certainty.
• Size: within the 86 RCTs, 162,796 participants.
• Who: adults at varying cardiovascular risk.
• How long: 12 to 88 months.
• Result: triglycerides reduced by about 15%, dose-dependent, high-certainty evidence.
• Funding: Research Support, Non-U.S. Gov't per the PubMed record.

Increasing LCn3 and ALA had little or no effect on serious adverse events, adiposity, lipids and blood pressure, except increasing LCn3 reduced triglycerides by ˜15% in a dose-dependent way (high-certainty evidence).

The oldest large trial, in 11,324 people soon after a heart attack, found 1 gram a day of n-3 PUFA lowered the combined endpoint of death, non-fatal myocardial infarction and stroke, reported only as a relative risk decrease. (Source 3)

• Randomized trial, Low certainty.
• Size: 11,324 patients; 2836 assigned n-3 PUFA alone.
• Who: patients surviving a myocardial infarction within the previous three months.
• How long: 3.5 years.
• Result: primary endpoint relative-risk decrease 10% (95% CI 1-18) by two-way analysis and 15% (2-26) by four-way analysis; death 14% (3-24) and 20% (6-33); cardiovascular death 17% (3-29) and 30% (13-44). The paper reports relative risk decreases; no absolute risk reduction or number needed to treat is given in the abstract.
• Funding: not stated in the abstract; the trial was open-label and had no placebo group (the comparator arm received no supplement)

Limit of this finding: Two cautions travel with these numbers. First, the trial reports two different analyses of the same data and the larger figures are the weaker ones: the primary two-way analysis gives 10%, 14% and 17%, while the four-way analysis gives 15%, 20% and 30%. A 30% reduction in cardiovascular death is the four-way figure and should never be quoted without saying so. Second, the primary two-way confidence interval runs from 1% to 18%, only just excluding zero, and the trial was open-label with no placebo, so neither patients nor doctors were blinded. The paper gives relative reductions only, with no absolute risk reduction.

Treatment with n-3 PUFA, but not vitamin E, significantly lowered the risk of the primary endpoint (relative-risk decrease 10% [95% CI 1-18] by two-way analysis, 15% [2-26] by four-way analysis). Benefit was attributable to a decrease in the risk of death (14% [3-24] two-way, 20% [6-33] four-way) and cardiovascular death (17% [3-29] two-way, 30% [13-44] four-way).

What the evidence does not support

A Cochrane review of 86 randomised trials found high-certainty evidence of little or no effect of long-chain omega-3 on all-cause mortality or cardiovascular events, with a slight reduction in coronary heart disease events at low certainty and a number needed to treat of 167. (Source 13)

• Systematic review, High certainty.
• Size: 86 RCTs, 162,796 participants; 143,693 participants and 11,297 deaths in the mortality analysis.
• Who: adults at varying cardiovascular risk, mainly in high-income countries.
• How long: 12 to 88 months.
• Result: all-cause mortality RR 0.97 (95% CI 0.93 to 1.01, high certainty); cardiovascular events RR 0.96 (0.92 to 1.01, high certainty); cardiovascular mortality RR 0.92 (0.86 to 0.99, moderate certainty); stroke RR 1.02 (0.94 to 1.12); arrhythmia RR 0.99 (0.92 to 1.06, low certainty); coronary heart disease mortality RR 0.90 (0.81 to 1.00, NNTB 334, low certainty); coronary heart disease events RR 0.91 (0.85 to 0.97, NNTB 167, low certainty)
• Funding: Research Support, Non-U.S. Gov't per the PubMed record.

Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.93 to 1.01; 143,693 participants; 11,297 deaths in 45 RCTs; high-certainty evidence), cardiovascular mortality (RR 0.92, 95% CI 0.86 to 0.99; 117,837 participants; 5658 deaths in 29 RCTs; moderate-certainty evidence), cardiovascular events (RR 0.96, 95% CI 0.92 to 1.01; 140,482 participants; 17,619 people experienced events in 43 RCTs; high-certainty evidence), stroke (RR 1.02, 95% CI 0.94 to 1.12; 138,888 participants; 2850 strokes in 31 RCTs; moderate-certainty evidence) or arrhythmia (RR 0.99, 95% CI 0.92 to 1.06; 77,990 participants; 4586 people experienced arrhythmia in 30 RCTs; low-certainty evidence). Increasing LCn3 may slightly reduce coronary heart disease mortality (number needed to treat for an additional beneficial outcome (NNTB) 334, RR 0.90, 95% CI 0.81 to 1.00; 127,378 participants; 3598 coronary heart disease deaths in 24 RCTs, low-certainty evidence) and coronary heart disease events (NNTB 167, RR 0.91, 95% CI 0.85 to 0.97; 134,116 participants; 8791 people experienced coronary heart disease events in 32 RCTs, low-certainty evidence).

In 25,871 generally healthy adults, 1 gram a day of marine omega-3 did not reduce major cardiovascular events or invasive cancer. (Source 14)

• Randomized trial, High certainty.
• Size: 25,871 participants, including 5106 Black participants.
• Who: US men aged 50 and over and women aged 55 and over at usual risk.
• How long: median 5.3 years.
• Result: major cardiovascular events HR 0.92 (95% CI 0.80 to 1.06, P=0.24); invasive cancer HR 1.03 (0.93 to 1.13, P=0.56); total myocardial infarction HR 0.72 (0.59 to 0.90); total stroke HR 1.04 (0.83 to 1.31); death from any cause HR 1.02 (0.90 to 1.15); no excess bleeding observed.
• Funding: National Institutes of Health and others.

Limit of this finding: The 0.72 figure for total myocardial infarction is the only nominally significant result here and it is a secondary end point, not one VITAL was designed to answer. VITAL's two primary end points, major cardiovascular events and invasive cancer, were both null, and the trial also tested vitamin D in the same two-by-two factorial design. The myocardial infarction number should not be quoted on its own as a benefit.

During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15).

In 15,480 people with diabetes and no established cardiovascular disease, 1 gram a day of omega-3 fatty acids did not reduce serious vascular events over more than seven years. (Source 15)

• Randomized trial, High certainty.
• Size: 15,480 participants.
• Who: adults with diabetes without evidence of atherosclerotic cardiovascular disease.
• How long: mean 7.4 years, adherence 76%.
• Result: serious vascular event 689 (8.9%) versus 712 (9.2%), rate ratio 0.97 (95% CI 0.87 to 1.08, P=0.55); vascular event or revascularisation 11.4% versus 11.5%, rate ratio 1.00 (0.91 to 1.09); death from any cause 9.7% versus 10.2%, rate ratio 0.95 (0.86 to 1.05)
• Funding: British Heart Foundation and others; comparator was olive oil.

Limit of this finding: The percentages here come from 15,480 people with diabetes randomised to a 1-gram capsule daily against an olive oil placebo, which is why the quote now includes that sentence. A figure such as "689 patients (8.9%)" means nothing without its denominator and dose.

We randomly assigned 15,480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease to receive 1-g capsules containing either n-3 fatty acids (fatty acid group) or matching placebo (olive oil) daily. The primary outcome was a first serious vascular event (i.e., nonfatal myocardial infarction or stroke, transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage). The secondary outcome was a first serious vascular event or any arterial revascularization. RESULTS: During a mean follow-up of 7.4 years (adherence rate, 76%), a serious vascular event occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P=0.55). The composite outcome of a serious vascular event or revascularization occurred in 882 patients (11.4%) and 887 patients (11.5%), respectively (rate ratio, 1.00; 95% CI, 0.91 to 1.09). Death from any cause occurred in 752 patients (9.7%) in the fatty acid group and in 788 (10.2%) in the placebo group (rate ratio, 0.95; 95% CI, 0.86 to 1.05). There were no significant between-group differences in the rates of nonfatal serious adverse events.

The largest trial of a high-dose EPA plus DHA preparation was stopped early for futility: 4 grams a day made no difference to major cardiovascular events against corn oil, and caused more gastrointestinal adverse events. (Source 16)

• Randomized trial, High certainty.
• Size: 13,078 patients randomised at 675 centres in 22 countries.
• Who: statin-treated adults at high cardiovascular risk with hypertriglyceridaemia and low HDL-C; median TG 240 mg/dL, 70% with diabetes.
• How long: enrolment 2014-2017, terminated January 2020 at 1384 of a planned 1600 events.
• Result: primary endpoint 785 (12.0%) on omega-3 CA versus 795 (12.2%) on corn oil, HR 0.99 (95% CI 0.90-1.09, P = .84); gastrointestinal adverse events 24.7% versus 14.7%.
• Funding: trial of a manufacturer's formulation (omega-3 carboxylic acids); PubMed records Research Support, Non-U.S. Gov't.

The primary end point occurred in 785 patients (12.0%) treated with omega-3 CA vs 795 (12.2%) treated with corn oil (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A greater rate of gastrointestinal adverse events was observed in the omega-3 CA group (24.7%) compared with corn oil-treated patients (14.7%).

A secondary analysis of that trial found that the patients who achieved the highest blood levels of EPA or DHA did no better than the comparator group, which argues against the idea that the null result came from inadequate dosing. (Source 17)

• Randomized trial, Moderate certainty.
• Size: 10,382 of the 13,078 participants had levels at baseline and 12 months.
• Who: the STRENGTH trial population.
• How long: 12-month levels, outcomes over the trial.
• Result: highest tertile versus corn oil: EPA adjusted HR 0.98 (95% CI 0.83-1.16, P = .81); DHA adjusted HR 1.02 (0.86-1.20)
• Funding: secondary analysis of the manufacturer-funded STRENGTH trial.

Limit of this finding: This compares people who happened to reach the highest blood levels of EPA or DHA with the comparator group. That comparison is observational even though it sits inside a randomised trial, because achieved blood level was not randomised. It is evidence against the idea that the trial failed through under-dosing; it is not a randomised test of high blood levels. Note also that the PubMed record itself prints "P = .85 for DHA." with the closing bracket missing; that is the source's own typo and has been left as it stands.

Compared with corn oil, the adjusted hazard ratios for the highest tertile of achieved plasma levels were 0.98 (95% CI, 0.83-1.16; P = .81) for EPA, and 1.02 (95% CI, 0.86-1.20; P = .85 for DHA. Sensitivity analyses based on changes in plasma and red blood cell levels of EPA and DHA and primary and secondary prevention subgroups showed similar results. CONCLUSIONS AND RELEVANCE: Among patients treated with ω-3 CA, the highest achieved tertiles of EPA and DHA were associated with neither benefit nor harm in patients at high cardiovascular risk.

Where the evidence is mixed

The label states plainly that lowering very high triglycerides with this drug can push LDL cholesterol and non-HDL cholesterol up in some people, and that its effect on cardiovascular death and illness has not been determined. (Source 18)

• Official position, Certainty not rated.
• Size: the same 84 subjects.
• Who: adults with severe hypertriglyceridemia.
• How long: 6 and 16 weeks.
• Result: no new numbers; a stated limitation.
• Funding: regulatory document.

Treatment with LOVAZA to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively. The effect of LOVAZA on the risk of pancreatitis has not been determined. The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined.

The trial that found a large benefit used an EPA-only ethyl ester at 4 grams a day against a mineral oil placebo, and reported more hospitalisation for atrial fibrillation and a borderline excess of serious bleeding. (Source 19)

• Randomized trial, Moderate certainty.
• Size: 8179 patients.
• Who: statin-treated patients with established cardiovascular disease or diabetes plus risk factors, fasting triglycerides 135 to 499 mg/dL.
• How long: median 4.9 years.
• Result: primary endpoint 17.2% versus 22.0%, HR 0.75 (95% CI 0.68 to 0.83, P<0.001), an absolute difference of 4.8 percentage points; cardiovascular death 4.3% versus 5.2%, HR 0.80 (0.66 to 0.98, P=0.03); hospitalisation for atrial fibrillation or flutter 3.1% versus 2.1% (P=0.004); serious bleeding 2.7% versus 2.1% (P=0.06)
• Funding: Funded by Amarin Pharma, the manufacturer of icosapent ethyl.

A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).

An independent cohort analysis designed to mimic both trials concluded the contrast between REDUCE-IT and STRENGTH is partly explained by the comparator oils, not by EPA versus EPA plus DHA. (Source 20)

• Cohort study, Low certainty.
• Size: 106,088 individuals in the Copenhagen General Population Study; 5684 meeting REDUCE-IT criteria and 6862 meeting STRENGTH criteria.
• Who: a general population cohort used to mimic the two trial designs.
• How long: followed for the median durations of the two trials, 4.9 and 3.5 years.
• Result: comparator oil arms: mimicking REDUCE-IT HR 1.07 (95% CI 1.04-1.10) versus mimicking STRENGTH 0.99 (0.98-0.99); active versus comparator 0.88 (0.84-0.93) mimicking REDUCE-IT against the trial's own 0.75 (0.68-0.83)
• Funding: Research Support, Non-U.S. Gov't per the PubMed record; independent of either trial sponsor.

Limit of this finding: This is an analysis of the Copenhagen General Population Study, an observational cohort selected to mimic each trial's entry criteria. It is not a head-to-head trial of the two comparator oils, so it can suggest an explanation for the difference between REDUCE-IT and STRENGTH but cannot establish one.

The contrasting results of REDUCE-IT vs. STRENGTH can partly be explained by a difference in the effect of comparator oils (mineral vs. corn), but not of active oils [eicosapentaenoic acid (EPA) vs. EPA + docosahexaenoic acid], on lipid traits and C-reactive protein. The unexplained additional 13% risk reduction in REDUCE-IT likely is through other effects of EPA or mineral oil.

A review commissioned in the manufacturer's interest reached the opposite conclusion, that mineral oil at the quantities used does not meaningfully affect trial conclusions. (Source 21)

• Expert review, not systematic, Very low certainty.
• Size: 80 studies employing mineral oil placebos were identified and data extracted.
• Who: clinical trials that used mineral oil as a placebo.
• How long: not applicable.
• Result: no pooled estimate; the review reports that biomarker and blood pressure changes with mineral oil were inconsistent and generally not statistically significant or clinically meaningful.
• Funding: Narrative review published in a European Heart Journal supplement; 6 of its 10 authors are employed by Amarin Pharma, Inc., the manufacturer of icosapent ethyl, the drug tested in REDUCE-IT. Read as a sponsor-aligned position.

Limit of this finding: Six of this review's ten authors work for Amarin Pharma, the maker of the drug whose trial result the mineral-oil criticism is aimed at. It is also a narrative review: it counted eighty studies but pooled nothing and reports no summary estimate. Treat it as the sponsor's defence of its own trial's placebo, not as an independent settlement of the question.

Based on available evidence, mineral oil does not appear to impact medication absorption or efficacy, or related clinical outcomes, and, therefore, does not meaningfully affect study conclusions when used as a placebo at the quantities used in clinical trials.

The GISSI-Prevenzione investigators' own interpretation calls the n-3 benefit clinically important and statistically significant, says vitamin E had no benefit, and leaves the effect on fatal cardiovascular events for further exploration. (Source 3)

• Randomized trial, Low certainty.
• Size: 11,324 people.
• Who: survivors of recent myocardial infarction in Italy.
• How long: 3.5 years.
• Result: no new numbers; this is the authors’ own summary of the trial.
• Funding: not stated in the abstract; the trial was open-label with no placebo arm.

Limit of this finding: This is the authors’ interpretation, not a separate result. The trial was open-label, so nobody was blinded, and its own primary confidence interval of 1% to 18% only just excludes no effect. Later and larger blinded trials at the same 1-gram dose, VITAL and ASCEND, found nothing.

INTERPRETATION: Dietary supplementation with n-3 PUFA led to a clinically important and statistically significant benefit. Vitamin E had no benefit. Its effects on fatal cardiovascular events require further exploration.

Where the research disagrees

Whether marine omega-3 fatty acids prevent cardiovascular events

• Bhatt and colleagues, REDUCE-IT (Amarin Pharma funded, EPA-only at 4 g/day against mineral oil), rct: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Source 19)
• Nicholls and colleagues, STRENGTH (EPA plus DHA at 4 g/day against corn oil), rct: Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events. (Source 16)
• Abdelhamid and colleagues, Cochrane review of 86 randomised trials, systematic-review: cardiovascular events (RR 0.96, 95% CI 0.92 to 1.01; 140,482 participants; 17,619 people experienced events in 43 RCTs; high-certainty evidence) (Source 13)

Whether the mineral oil comparator used in REDUCE-IT distorted its result

• Doi, Langsted and Nordestgaard, Copenhagen General Population Study analysis, cohort: The contrasting results of REDUCE-IT vs. STRENGTH can partly be explained by a difference in the effect of comparator oils (mineral vs. corn), but not of active oils [eicosapentaenoic acid (EPA) vs. EPA + docosahexaenoic acid], on lipid traits and C-reactive protein. (Source 20)
• Olshansky and colleagues, narrative review in a European Heart Journal supplement defending the comparator - 6 of its 10 authors are employed by Amarin Pharma, Inc., the maker of icosapent ethyl, the drug tested in REDUCE-IT (sponsor-aligned), narrative-review: There was no consistent evidence that mineral oil in the amounts used in the REDUCE-IT or Effect of Vascepa on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy (EVAPORATE) trials affects absorption of essential nutrients or drugs, including statins. (Source 21)

Whether EPA alone differs from EPA plus DHA

• Doi and colleagues, comparing the two trial designs in a cohort, cohort: but not of active oils [eicosapentaenoic acid (EPA) vs. EPA + docosahexaenoic acid], on lipid traits and C-reactive protein. The unexplained additional 13% risk reduction in REDUCE-IT likely is through other effects of EPA or mineral oil. (Source 20)
• Nissen and colleagues, secondary analysis of achieved EPA and DHA levels in STRENGTH, rct: Among patients treated with ω-3 CA, the highest achieved tertiles of EPA and DHA were associated with neither benefit nor harm in patients at high cardiovascular risk. (Source 17)

How much

• Reference intake: Dosing is set by the prescriber. As a position, the FDA label states the daily dose is 4 grams per day, taken either as a single 4-gram dose of four capsules or as two 2-gram doses of two capsules twice daily, with capsules swallowed whole. (Source 8)
• Upper limit: The label sets no separate maximum: 4 grams per day is both the stated dose and the ceiling it describes for the approved indication. For context, the dose-response the atrial fibrillation meta-analysis found was an increasing hazard ratio per 1 gram higher dose, and the 4-gram trials showed the larger effect. (Source 6)
• Studied: The two approval trials gave 4 grams a day for 6 and 16 weeks to adults whose baseline triglycerides were between 500 and 2,000 mg/dL. (Source 22)
• Studied: VITAL gave 1 gram a day of marine n-3 to 25,871 adults for a median 5.3 years; ASCEND gave 1-gram capsules daily to 15,480 people with diabetes for a mean 7.4 years against olive oil. (Source 14)
• Studied: STRENGTH gave 4 grams a day of an EPA plus DHA carboxylic acid formulation to 6539 statin-treated patients against corn oil; REDUCE-IT gave 2 grams twice daily of EPA-only icosapent ethyl, a total of 4 grams a day, to 8179 patients against mineral oil. (Source 16)
• Studied: The trial of recurrent atrial fibrillation recorded in the label used 8 grams a day for 7 days then 4 grams a day for 23 weeks. (Source 4)

A common belief, and what the research shows

The belief: Prescription fish oil is a heart drug: it lowers triglycerides, so it must lower heart attack and death risk too.

What the research shows: The label for the prescription product says the opposite of settled. On cardiovascular outcomes it states: "The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined." The Cochrane review of 86 randomised trials rates the absence of an effect on cardiovascular events as high-certainty evidence, and in the one large 4-gram EPA plus DHA outcome trial the result was "no significant difference in a composite outcome of major adverse cardiovascular events". Lowering triglycerides in these trials also raised LDL cholesterol in some people.

Questions and answers

What is it?

It is prescription-strength marine omega-3, supplied as the ethyl esters of EPA and DHA in a liquid-filled gel capsule. Each 1-gram capsule holds at least 900 mg of those ethyl esters, about 465 mg of EPA and about 375 mg of DHA, sourced from fish oils. It is a regulated drug with one approved indication, not a food supplement, and it is a different product from EPA-only icosapent ethyl. (Source 23)

What does it do in the body?

Its measurable job is lowering triglycerides, and it does that reliably: Cochrane rated a roughly 15% dose-dependent reduction as high-certainty evidence. How it does so is not fully understood; the label lists several candidate mechanisms in the liver and notes that EPA and DHA are poor substrates for the enzymes that build triglyceride. It does not reliably lower the risk of heart attack, stroke or death in the trials that looked. (Source 1)

Is it good or bad for you?

Good for one narrow job, unproven for the one most people assume. In adults with triglycerides at or above 500 mg/dL it cuts them by about 45%, though LDL cholesterol rose 44.5% in the same trials and the label asks for monitoring so LDL does not climb too far. For preventing cardiovascular events the literature is split and Cochrane grades the no-effect result as high certainty. There is also a dose-related atrial fibrillation signal across the outcome trials. (Source 18)

How do you get more of it?

The prescription form comes only on prescription, at a dose the prescriber sets; the label's stated dose is 4 grams a day with meals. EPA and DHA themselves come from oily fish and from over-the-counter fish oil, and the Cochrane review covered trials of supplements, enriched foods and dietary advice. Adding supplement omega-3 on top of the prescription dose adds to the same exposure, and the atrial fibrillation signal was larger above 1 gram a day. (Source 8)

If it is harmful, what reduces it?

Nothing in the literature we searched describes a need to clear omega-3 from the body or a method for doing so, and no withdrawal syndrome is described. The relevant harm questions are about continuing rather than clearing: the bleeding-time effect with anticoagulants, which the label says has not been properly studied, and the atrial fibrillation excess seen in the first two to three months in people who already had atrial fibrillation. (Source 5)

Why might someone be low in it or missing it?

No one is deficient in a drug. For the underlying fatty acids, low intake comes from eating little oily fish. For a high triglyceride level, which is what the drug treats, the label names the things to look for first: diabetes, an underactive thyroid, obesity and medicines that raise triglycerides such as beta blockers, thiazides and estrogens, and it asks that these be addressed before drug treatment is considered. (Source 2)

Which whole foods contain it or feed it?

Oily fish is the dietary source of the same EPA and DHA; the drug's own esters are obtained from the oil of several fish sources. The Cochrane review covered trials of oily fish and of omega-3-rich or enriched foods as well as capsules, and reported that there is little evidence of effects of eating fish on the cardiovascular outcomes it assessed. (Source 13)

What happens if you do not have it?

For someone with severe hypertriglyceridaemia who is not taking it, the triglyceride level stays where the diet and the underlying causes leave it: in the approval trials the placebo group's median triglycerides rose 6.7% over 6 to 16 weeks while the treated group's fell 44.9%. Whether that matters for outcomes is unresolved, because the label states the effect on pancreatitis risk has not been determined, and the large outcome trials of EPA plus DHA found no reduction in cardiovascular events. (Source 18)

How can you test for it?

The test that matters is a fasting triglyceride level, and the label asks for it twice: assess triglycerides carefully before starting, and confirm with laboratory studies that lipid levels are consistently abnormal before beginning treatment, because a single reading can mislead. The label also asks for LDL cholesterol to be monitored during treatment, since it can rise. Blood EPA and DHA levels can be measured, and in the STRENGTH secondary analysis the highest achieved levels were associated with neither benefit nor harm, so those levels did not predict outcome. (Source 2)

References

1. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 12.1 Mechanism of Action. 2026. Read the source
2. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 1 INDICATIONS AND USAGE (with its subsections, in document order). 2026. Read the source
3. Lancet (London, England). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.. 1999. PMID 10465168. Read the source
4. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 5.3 Recurrent Atrial Fibrillation (AF) or Flutter. 2026. Read the source
5. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 7.1 Anticoagulants or Other Drugs Affecting Coagulation. 2026. Read the source
6. Circulation. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.. 2021. PMID 34612056, DOI 10.1161/CIRCULATIONAHA.121.055654. Read the source
7. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 5.2 Fish Allergy. 2026. Read the source
8. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 2 DOSAGE AND ADMINISTRATION. 2026. Read the source
9. The Cochrane database of systematic reviews. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.. 2020. PMID 32114706, DOI 10.1002/14651858.CD003177.pub5. Read the source
10. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 6.1 Clinical Trials Experience in full: narrative text, Table 1 with the footnote on its Adverse Reaction heading, and the Digestive System, Metabolic and Nutritional Disorders and Skin subsections that follow it. 2026. Read the source
11. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 6.2 Postmarketing Experience. 2026. Read the source
12. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 14.1 Severe Hypertriglyceridemia, Table 2 (median baseline and percent change in lipid parameters). 2026. Read the source
13. The Cochrane database of systematic reviews. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.. 2020. PMID 32114706, DOI 10.1002/14651858.CD003177.pub5. Read the source
14. The New England journal of medicine. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.. 2019. PMID 30415637, DOI 10.1056/NEJMoa1811403. Read the source
15. The New England journal of medicine. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.. 2018. PMID 30146932, DOI 10.1056/NEJMoa1804989. Read the source
16. JAMA. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.. 2020. PMID 33190147, DOI 10.1001/jama.2020.22258. Read the source
17. JAMA cardiology. Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.. 2021. PMID 33993205, DOI 10.1001/jamacardio.2021.1157. Read the source
18. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 14.1 Severe Hypertriglyceridemia (narrative text following Table 2). 2026. Read the source
19. The New England journal of medicine. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.. 2019. PMID 30415628, DOI 10.1056/NEJMoa1812792. Read the source
20. European heart journal. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs.. 2021. PMID 34455435, DOI 10.1093/eurheartj/ehab555. Read the source
21. European heart journal supplements : journal of the European Society of Cardiology. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.. 2020. PMID 33061866, DOI 10.1093/eurheartj/suaa117. Read the source
22. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 14.1 Severe Hypertriglyceridemia (narrative text preceding Table 2). 2026. Read the source
23. DailyMed / Waylis Therapeutics (SPL published 11 March 2026). LOVAZA (omega-3-acid ethyl esters) capsule - FDA label, 11 DESCRIPTION. 2026. Read the source